• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Lexaria Bioscience Corp.

    10/1/25 2:46:31 PM ET
    $LEXX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LEXX alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0001348362
    LEXARIA CORP.
    Lexaria Corp.
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    Lexaria Bioscience Corp.
    Jurisdiction of Incorporation/Organization
    NEVADA
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    Lexaria Bioscience Corp.
    Street Address 1 Street Address 2
    100 - 740 MCCURDY ROAD
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    KELOWNA BRITISH COLUMBIA, CANADA V1X 2P7 250-765-6424

    3. Related Persons

    Last Name First Name Middle Name
    Bunka Christopher
    Street Address 1 Street Address 2
    100 - 740 McCurdy Road
    City State/Province/Country ZIP/PostalCode
    Kelowna BRITISH COLUMBIA, CANADA V1X 2P7
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Docherty John
    Street Address 1 Street Address 2
    100 - 740 McCurdy Road
    City State/Province/Country ZIP/PostalCode
    Kelowna BRITISH COLUMBIA, CANADA V1X 2P7
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Christopher Richard
    Street Address 1 Street Address 2
    100 - 740 McCurdy Road
    City State/Province/Country ZIP/PostalCode
    Kelowna BRITISH COLUMBIA, CANADA V1X 2P7
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Shankman Michael
    Street Address 1 Street Address 2
    100 - 740 McCurdy Road
    City State/Province/Country ZIP/PostalCode
    Kelowna BRITISH COLUMBIA, CANADA V1X 2P7
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Baxter Nicholas
    Street Address 1 Street Address 2
    100 - 740 McCurdy Road
    City State/Province/Country ZIP/PostalCode
    Kelowna BRITISH COLUMBIA, CANADA V1X 2P7
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    McKechnie William Edward
    Street Address 1 Street Address 2
    100 - 740 McCurdy Road
    City State/Province/Country ZIP/PostalCode
    Kelowna BRITISH COLUMBIA, CANADA V1X 2P7
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Reese Albert
    Street Address 1 Street Address 2
    100 - 740 McCurdy Road
    City State/Province/Country ZIP/PostalCode
    Kelowna BRITISH COLUMBIA, CANADA V1X 2P7
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Bhullar Bal
    Street Address 1 Street Address 2
    100 - 740 McCurdy Road
    City State/Province/Country ZIP/PostalCode
    Kelowna BRITISH COLUMBIA, CANADA V1X 2P7
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
    X Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
    X $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
       Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2025-09-29    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

       Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
    X Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
       Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number    None
    H.C. WAINWRIGHT & CO. 375
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    None None
    Street Address 1 Street Address 2
    420 Park Avenue 4th Floor
    City State/Province/Country ZIP/Postal Code
    New York NEW YORK 10022
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
    X Foreign/non-US
    ILLINOIS
    NEW YORK

    13. Offering and Sales Amounts

    Total Offering Amount $4,000,000 USD
    or    Indefinite
    Total Amount Sold $4,000,000 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    5

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $280,000 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Commission represents 7% of the offering amount, including for the registered shares that form part of the combined offering of 1 registered share and 1 unregistered warrant

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    Lexaria Bioscience Corp. /Richard Christopher/ Richard Christopher CEO 2025-10-01

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $LEXX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LEXX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LEXX
    SEC Filings

    View All

    SEC Form DEF 14A filed by Lexaria Bioscience Corp.

    DEF 14A - Lexaria Bioscience Corp. (0001348362) (Filer)

    12/10/25 10:56:16 AM ET
    $LEXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Lexaria Bioscience Corp.

    EFFECT - Lexaria Bioscience Corp. (0001348362) (Filer)

    12/10/25 12:15:22 AM ET
    $LEXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Lexaria Bioscience Corp.

    424B3 - Lexaria Bioscience Corp. (0001348362) (Filer)

    12/9/25 4:30:38 PM ET
    $LEXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LEXX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval

    Positive results in a recent animal study strongly supports first-ever human investigation for DehydraTECH-liraglutide in an oral capsule format KELOWNA, BC / ACCESSWIRE / January 15, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that it has received the necessary independent ethics board approval required for its contract research organization ("CRO") to begin to implement and execute human pilot study GLP-1-H25-5 (the "Study"). The Study will compare an oral version of liraglutide, formulated from the DehydraTECH-processing of Saxenda® ("DehydraTECH-liraglutide") to the convent

    1/15/25 9:20:00 AM ET
    $LEXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

    Oral DehydraTECH-tirzepatide evidenced reduced adverse events of 47% compared to injected Zepbound®Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable to injected Zepbound® KELOWNA, BC / ACCESSWIRE / January 14, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces partial final results showcasing the tolerability and glycemic control efficacy findings from human study GLP-1-H24-3 (the "Study"), comparing an oral version of DehydraTECH-processed Zepbound® ("DehydraTECH-tirzepatide") to conventional injected Zepbound®.The injected Zepbound® produc

    1/14/25 9:10:00 AM ET
    $LEXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lexaria's Registered GLP-1 Study #4 Begins Dosing

    Registered Phase-1b 12-week study will investigate safety, diabetes control, and weight loss KELOWNA, BC / ACCESSWIRE / December 19, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has begun dosing in the Company's Phase 1b, 12-week chronic study GLP-1-H24-4, (the "Study"). The Study is designed mainly to determine whether Lexaria's proprietary DehydraTECH technology improves the safety and effectiveness of existing GLP-1 drugs."Achieving the first patient, first dose Study milestone is a critical achievement," said John Docherty, President and Chief Scientific Officer of Lexaria Bioscience

    12/19/24 9:05:00 AM ET
    $LEXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LEXX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bunka Christopher bought $25,241 worth of shares (27,500 units at $0.92) (SEC Form 4)

    4 - Lexaria Bioscience Corp. (0001348362) (Issuer)

    7/30/25 5:12:54 PM ET
    $LEXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mckechnie William Edward bought $4,532 worth of shares (5,000 units at $0.91), increasing direct ownership by 38% to 18,191 units (SEC Form 4)

    4 - Lexaria Bioscience Corp. (0001348362) (Issuer)

    7/30/25 12:37:08 PM ET
    $LEXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CSO Docherty John Martin bought $4,989 worth of shares (5,376 units at $0.93) (SEC Form 4)

    4 - Lexaria Bioscience Corp. (0001348362) (Issuer)

    7/30/25 11:34:10 AM ET
    $LEXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LEXX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bunka Christopher bought $25,241 worth of shares (27,500 units at $0.92) (SEC Form 4)

    4 - Lexaria Bioscience Corp. (0001348362) (Issuer)

    7/30/25 5:12:54 PM ET
    $LEXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mckechnie William Edward bought $4,532 worth of shares (5,000 units at $0.91), increasing direct ownership by 38% to 18,191 units (SEC Form 4)

    4 - Lexaria Bioscience Corp. (0001348362) (Issuer)

    7/30/25 12:37:08 PM ET
    $LEXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CSO Docherty John Martin bought $4,989 worth of shares (5,376 units at $0.93) (SEC Form 4)

    4 - Lexaria Bioscience Corp. (0001348362) (Issuer)

    7/30/25 11:34:10 AM ET
    $LEXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LEXX
    Leadership Updates

    Live Leadership Updates

    View All

    Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

    Dr. Gibson joining Lexaria's new scientific advisor board KELOWNA, BC / ACCESSWIRE / December 17, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the appointment of Dr. Michael Gibson as its new Chief Medical Advisor. Dr. Gibson will collaborate directly with President John Docherty as Lexaria's patented DehydraTECH drug delivery platform continues to expand its applications in GLP-1 and hypertension.C. Michael Gibson M.S., M.D., is an interventional cardiologist, cardiovascular researcher & educator. He is the CEO of the combined non-profit Baim and PERFUSE research institutes at Harvard Medic

    12/17/24 9:10:00 AM ET
    $LEXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lexaria Appoints Michael Shankman as Chief Financial Officer

    KELOWNA, BC / ACCESSWIRE / October 1, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the appointment of Michael Shankman, CPA, as Chief Financial Officer (CFO) effective immediately. As a member of the executive leadership team, Mr. Shankman will lead the Company's financial operations."Mike is an accomplished individual who brings a wealth of financial and regulatory knowledge and experience to the table," said Richard Christopher, Chief Executive Officer of Lexaria. "On behalf of the entire Lexaria team, I'm thrilled to welcome Mike as our CFO as we continue to strengthen our executive tea

    10/1/24 9:25:00 AM ET
    $LEXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lexaria Appoints Nelson Cabatuan as Chief Financial Officer

    KELOWNA, BC / ACCESSWIRE / March 14, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the appointment of Nelson Cabatuan, CPA, as Chief Financial Officer (CFO) effective immediately. As a member of the executive leadership team, Mr. Cabatuan will lead the Company's financial operations."Nelson's deep financial leadership experience will be instrumental to the execution of Lexaria's long-term growth strategy as we continue to maximize the potential use of our DehydraTECH platform for GLP-1 and other therapeutic applications with high unmet medical needs," said Chris Bunka, Chief Executive Officer

    3/14/24 9:20:00 AM ET
    $LEXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LEXX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Lexaria Bioscience Corp.

    SC 13G/A - Lexaria Bioscience Corp. (0001348362) (Subject)

    11/14/24 4:11:11 PM ET
    $LEXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Lexaria Bioscience Corp.

    SC 13D/A - Lexaria Bioscience Corp. (0001348362) (Subject)

    9/23/24 1:28:02 PM ET
    $LEXX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Lexaria Bioscience Corp.

    SC 13D/A - Lexaria Bioscience Corp. (0001348362) (Subject)

    8/6/24 4:11:10 PM ET
    $LEXX
    Biotechnology: Pharmaceutical Preparations
    Health Care